Roman Butler Fullerton & Co’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-8,837
| Closed | -$1.26M | – | 217 |
|
|
2023
Q4 | $1.26M | Buy |
+8,837
| New | +$1.26M | 0.49% | 54 |
|
|
2023
Q1 | – | Sell |
-11,864
| Closed | -$1.28M | – | 201 |
|
|
2022
Q4 | $1.28M | Buy |
11,864
+1,305
| +12% | +$141K | 0.66% | 46 |
|
|
2022
Q3 | $1.14M | Buy |
+10,559
| New | +$1.14M | 0.72% | 36 |
|
|
2020
Q3 | – | Sell |
-7,422
| Closed | -$905K | – | 159 |
|
|
2020
Q2 | $905K | Buy |
+7,422
| New | +$905K | 0.65% | 54 |
|